CT:AUP Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol AUPH.

This company has cross-listed shares that trade in the U.S. as the symbol AUPH.

16.76 CAD
As of 07/30/2021

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  09/19/2000
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   2,147,894,528 CAD
Current dividend yield:   0.00%
Sedol:      BFWLBZ7

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy